Español
Català
English

Investing in
life sciences

About Us

We are a VC fund focused on investing in early-stage companies in the healthcare sector: biotechnology, medical devices and eHealth.

Invivo Ventures is managed by Invivo Capital Partners, promoted by Luis Pareras and Albert Ferrer, with the experience gained through the first fund Healthequity. The fund was registered to the Comisión Nacional del Mercado de Valores (CNMV) in March 2019 and has achieved a final closing of 60M €.

We are a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyse and make investments to provide value to the invested company. We also have a network of contacts and key strategic relationships in the health ecosystem.

Our company is financed by the European Investment Fund, the Instituto de Crédito Oficial, the Institut Català de Finances, the Institut Valencià de Finances, the Ajuntament de Barcelona and other private investors.

Investment strategy

Projects

Projects

We seek projects according to the following criteria:

  • Powerful proof of concept: solid scientific package with convincing results in animal models.
  • Unique technology and disruptive product: scientific innovation should represent a substantial improvement over current technology.
  • Roadmap and clearly defined costs.
  • Multidisciplinary and committed team.
  • Specific indications that can be complemented with line extensions.
  • Strong protection of intellectual property or the ability to generate strong entry barriers for competitors.
Investment size

Investment size

We set initial investments in the range of 0.5-2M €, and after achieving pre-established milestones we can reach up to 4M €.

State of development

State of development

We focus on investing in companies in early stages, mainly in the technology transfer phase. In the case of biotechnology companies, they should have a solid proof of concept in animal models, and in the case of medical devices or digital health companies, a prototype close to the market.

Geographical focus

Geographical focus

We invest in Spain a significant amount of the funds raised, while a smaller percentage is considered for investments syndicated with other funds in European companies.

Sector

Sector

We want to diversify risks by investing in companies in different stages and different sub-sectors within the biomedical area, such as biotechnology, medical devices and digital health.

Portfolio

Healthequity is a VC fund focused on investing in early-stage companies in the Healthcare sector. Promoted by the Medical Association of Barcelona and the financial group Riva y Garcia, it was registered with the CNMV and founded in 2012.

The fund finished its first investment period in early 2019.

Team

Luis Pareras
Partner
Albert Ferrer
Partner
Laura Rodriguez
Principal
Oscar Ferrer
Investment Analyst
Gemma Guinart
Investment Analyst
Marta Tort
Investment Analyst
Begoña Aguirre
Executive Assistant

DIFFICULT INDICATIONS

Glioblastoma remains one of the most pressing clinical needs in medicine. Its prognosis is dismal and current standard of care involves maximal safe surgical resection, radiotherapy and chemotherapy. News drugs are on the way though: many groups across the world are trying to solve the challenge. It is indeed a difficult challenge because (1) the blood brain barrier limits PK/PD, (2) new studies confirm glioblastoma stem cells confer resistance, (3) clinical trials are usually done in recurrent patients, and (4) no monotherapy strategy will probably eradicate it completely. It is a especially dear field to me because as some of you may know I used to operate them as a former neurosurgeon and I’ve seen first-hand how aggressive they are.
All big unsolved clinical needs may be a good investment opportunity. Here’s a conceptual map with some of the leading-edge alternatives and targets that are being moved forward.
You can find all my quick notes at #quick_notes_LP

DIFFICULT INDICATIONS: PANCREATIC CANCER

The higher the clinical need and the prevalence, the higher the effort from scientists around the world in trying to solve a problem. Pancreatic ductal adenocarcinoma (PDAC) remains one of the highest unsolved clinical needs today. It is a devastating disease with an unfavorable outcome and is projected to become the second deadliest cancer by 2030. Currently the overall 5-year survival rate is less than 10% despite all efforts. But new therapies are being pushed forward every month, the rhythm of innovation here is extraordinary.
All big unsolved clinical needs may be a good investment opportunity. Here’s a conceptual map (by no means complete) with some of the leading-edge alternatives and targets that are being moved forward. A map just to navigate the landscape and avoid getting lost amid all the different categories and approaches.
You can find all my quick notes at #quick_notes_LP

LAUNCHING A BIOTECH STARTUP

Some advice for scientists willing to become entrepreneurs, here are six things you should think carefully before embarking on your journey… (OPENING THREAD: some slides I used in a lecture @EU_Commission last month)

#quick_notes_LP



More...

Contact

We are here!

Passeig de Gràcia, 54, 2n D
08007 Barcelona

+34 93 018 51 65

info@invivo.capital

Fondo financiado por FEDER:

Instituto de Crédito Oficial

TOP